A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors
A study for patients with locally advanced or metastatic solid tumors using study drug demcizumab
Sponsor: OncoMed Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ6730
U.S. Govt. ID: NCT02722954
Contact: Catherine Shu: 646-317-3141 / cas2145@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer stem cells, in addition to the remaining cancer cells, and it may also prevent the growth of new blood vessels that tumors need to grow and spread. Demcizumab, used in this study, is experimental.
This study is closed
Investigator
Catherine Shu, MD
Do You Qualify?
Have you been diagnosed with advanced solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Catherine Shu
cas2145@cumc.columbia.edu
646-317-3141
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE